A New Adjuvant MTOM Mediates Mycobacterium tuberculosis Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL-2+ T Cells
- PMID: 28572807
- PMCID: PMC5436497
- DOI: 10.3389/fimmu.2017.00585
A New Adjuvant MTOM Mediates Mycobacterium tuberculosis Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL-2+ T Cells
Abstract
The only licensed vaccine Mycobacterium bovis Bacillus Calmette-Guérin (BCG) cannot prevent the prevalence of tuberculosis (TB), which remains a major public health problem worldwide. A more effective TB vaccine than BCG is urgently needed. Subunit vaccine is a promising strategy, and suitable adjuvants will benefit the development of effective TB subunit vaccines. MTO, consisting of monophosphoryl lipid A (MPLA), trehalose-6,6'-dibehenate (TDB), and MF59, was developed as an adjuvant of TB vaccine because of its ability to evoke the Th1-type T cell responses, while it is insufficient to induce single and multifunctional IL-2+ T cells and has a limited ability to confer protection against Mycobacterium tuberculosis infection. Heat-killed Mycobacterium vaccae (Mv), which can evoke cytotoxic CD8+ and CD4+ T cell responses and has adjuvanticity, was, in this study, combined with MTO to produce a new adjuvant, called MTOM. The TB fusion protein Rv3407-PhoY2-Ag85A-Rv2626c-RpfB (WH121) was mixed with MTO, Mv, and MTOM to produce three subunit vaccines, and the protective efficacy and immune responses were compared in C57BL/6 mice. WH121/MTOM provided better protection against TB than the other two vaccines, matching the performance of BCG vaccine. MTOM showed stronger ability to increase single and multifunctional IL-2+ T cells and induce Th1-type responses than MTO or Mv. Therefore, MTOM might be a promising adjuvant that could contribute to the development of TB subunit vaccines.
Keywords: IL-2+ T cells; MTOM; Mycobacterium tuberculosis; Th1-type response; adjuvant.
Figures




Similar articles
-
Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.Front Immunol. 2020 Sep 30;11:575504. doi: 10.3389/fimmu.2020.575504. eCollection 2020. Front Immunol. 2020. PMID: 33117374 Free PMC article.
-
Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.PLoS One. 2015 Mar 30;10(3):e0122560. doi: 10.1371/journal.pone.0122560. eCollection 2015. PLoS One. 2015. PMID: 25822536 Free PMC article.
-
Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre- and post-exposure infections by driving Th1-type T cell immunity.Oncotarget. 2016 Sep 27;7(39):63804-63815. doi: 10.18632/oncotarget.11542. Oncotarget. 2016. PMID: 27566581 Free PMC article.
-
[Novel vaccines against M. tuberculosis].Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
-
Tuberculosis vaccines: time to think about the next generation.Semin Immunol. 2013 Apr;25(2):172-81. doi: 10.1016/j.smim.2013.04.006. Epub 2013 May 21. Semin Immunol. 2013. PMID: 23706597 Review.
Cited by
-
Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster.Tuberculosis (Edinb). 2022 May;134:102186. doi: 10.1016/j.tube.2022.102186. Epub 2022 Feb 26. Tuberculosis (Edinb). 2022. PMID: 35245739 Free PMC article.
-
Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.Front Immunol. 2020 Sep 30;11:575504. doi: 10.3389/fimmu.2020.575504. eCollection 2020. Front Immunol. 2020. PMID: 33117374 Free PMC article.
-
Developing New Anti-Tuberculosis Vaccines: Focus on Adjuvants.Cells. 2021 Jan 5;10(1):78. doi: 10.3390/cells10010078. Cells. 2021. PMID: 33466444 Free PMC article. Review.
-
Bridging the gaps to overcome major hurdles in the development of next-generation tuberculosis vaccines.Front Immunol. 2023 Aug 11;14:1193058. doi: 10.3389/fimmu.2023.1193058. eCollection 2023. Front Immunol. 2023. PMID: 37638056 Free PMC article. Review.
-
Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development.NPJ Vaccines. 2024 Mar 9;9(1):57. doi: 10.1038/s41541-024-00834-y. NPJ Vaccines. 2024. PMID: 38461350 Free PMC article. Review.
References
-
- Global Tuberculosis Report 2016. Geneva, Switzerland: United Nations, World Health Organization (WHO) (2016). Available from: http://www.who.int/tb/publications/global_report/en/
-
- Yao S, Huang D, Chen CY, Halliday L, Wang RC, Chen ZW. CD4+ T cells contain early extrapulmonary tuberculosis (TB) dissemination and rapid TB progression and sustain multieffector functions of CD8+ T and CD3- lymphocytes: mechanisms of CD4+ T cell immunity. J Immunol (2014) 192(5):2120–32.10.4049/jimmunol.1301373 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials